The medicine, angioplasty, or surgery study: a randomized controlled clinical trial of three therapeutic strategies for multi-vessel coronary artery disease

Conditions

Coronary Artery Disease (CAD) Circulatory System Coronary Artery Disease (CAD)

Thiago Luis Scudeler, Michael E. Farkouh, Whady Hueb, Paulo Cury Rezende, Alessandro Gonçalves Campolina et al. (10 authors)

BMJ Open2022-09-018 citations

10.1136/bmjopen-2022-062378

Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial

Eduardo Gomes Lima, David M. Charytan, Whady Hueb, Diogo Freitas Cardoso de Azevedo, Cibele Larrosa Garzillo et al. (13 authors)

Nephrology Dialysis Transplantation2018-12-0617 citations

10.1093/ndt/gfy379

Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial.

Brandão SMG, Rezende PC, Rocca HB, Ju YT, de Lima ACP, Takiuti ME, Hueb W, Bocchi EA.

2018-11-038 citations

10.1186/s12962-018-0158-z

Impact of diabetes mellitus on ischemic cardiomyopathy. Five-year follow-up. REVISION-DM trial.

Hueb T, Rocha MS, Siqueira SF, Nishioka SADO, Peixoto GL, Saccab MM, Lima EG, Garcia RMR, Ramires JAF, Kalil Filho R, Martinelli Filho M.

2018-03-153 citations

10.1186/s13098-018-0320-y

Impact of Chronic Kidney Disease on Long-Term Outcomes in Type 2 Diabetic Patients With Coronary Artery Disease on Surgical, Angioplasty, or Medical Treatment.

Lima EG, Hueb W, Gersh BJ, Rezende PC, Garzillo CL, Favarato D, Hueb AC, Rahmi Garcia RM, Franchini Ramires JA, Filho RK.

2016-01-1220 citations

10.1016/j.athoracsur.2015.10.036

Long-term analysis of left ventricular ejection fraction in patients with stable multivessel coronary disease undergoing medicine, angioplasty or surgery: 10-year follow-up of the MASS II trial

Cibele Larrosa Garzillo, Whady Hueb, Bernard J. Gersh, Eduardo Gomes Lima, Paulo Cury Rezende et al. (13 authors)

European Heart Journal2013-07-0421 citations

10.1093/eurheartj/eht201

Effect of complete revascularization on 10-year survival of patients with stable multivessel coronary artery disease: MASS II trial.

Vieira RD, Hueb W, Gersh BJ, Lima EG, Pereira AC, Rezende PC, Garzillo CL, Hueb AC, Favarato D, Soares PR, Ramires JA, Kalil Filho R.

2012-09-0148 citations

10.1161/circulationaha.111.084236

Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial.

Vieira RD, Hueb W, Hlatky M, Favarato D, Rezende PC, Garzillo CL, Lima EG, Soares PR, Hueb AC, Pereira AC, Ramires JA, Kalil Filho R.

2012-09-0130 citations

10.1161/circulationaha.111.084442

Genetic variants of diabetes risk and incident cardiovascular events in chronic coronary artery disease.

Sousa AG, Lopes NH, Hueb WA, Krieger JE, Pereira AC.

2011-01-206 citations

10.1371/journal.pone.0016341

Five-year follow-up of a randomized comparison between off-pump and on-pump stable multivessel coronary artery bypass grafting. The MASS III Trial.

Hueb W, Lopes NH, Pereira AC, Hueb AC, Soares PR, Favarato D, Vieira RD, Lima EG, Garzillo CL, Paulitch Fda S, César LA, Gersh BJ, Ramires JA.

2010-09-0177 citations

10.1161/circulationaha.109.924258

Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.

Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JA.

2010-08-23224 citations

10.1161/circulationaha.109.911669

TCF7L2 polymorphism rs7903146 is associated with coronary artery disease severity and mortality.

Sousa AG, Marquezine GF, Lemos PA, Martinez E, Lopes N, Hueb WA, Krieger JE, Pereira AC.

2009-11-1744 citations

10.1371/journal.pone.0007697

Interventions

In this trial, all patients were placed on an optimal medical regiment consisting of a stepped-care approach using nitrates, aspirin, beta-blockers, calcium channel blockers, Angiotensin Converting En

Eligibility

Inclusion criteria

Inclusion criteria: 1. Stable angina 2. Preserved left ventricular function 3. Two or three vessel disease

Exclusion criteria

Exclusion criteria: 1. Unstable angina or acute myocardial infarction requiring emergency revascularization 2. Ventricular aneurism requiring surgical repair 3. Left ventricular ejection fraction of less than 40% 4. A history of Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG) and single vessel disease 5. A history of congenital heart disease 6. Valvular heart disease or cardiomyopathy 7. Inability to understand or cooperate with the protocol requirements or return for follow-up 8. Left main coronary artery stenosis of 50% or more 9. Suspected or known pregnancy 10. Other coexisting condition that was a contraindication to CABG or PCI

Design outcomes

Primary

Measure	Time frame
1. Non-fatal myocardial infarction 2. Cardiac death 3. Refractory angina requiring revascularization	—

Secondary

Measure	Time frame
1. Quality of life 2. Cost comparison 3. Cerebro-Vascular Accident (CVA)	—

Countries

Brazil

Outcome results

None listed